Consumers in Uzbekistan are expected to continue to benefit from an increase in purchasing power in 2020, even if slightly the growth rate may be restricted due to potential financial effects of COVID-19. This growing purchasing power is expected to be visible in volume sales of nappies, diapers, and pants that come under the paediatric dermatologicals.
The Uzbek company Radiks is expected to increase its value share in 2020, ranking third in terms of its company share, and demonstrating some recovery from previously declining value shares in the latter half of the review period. The Radiks brand, however, is expected to rank second in 2020, as the company continues to supply consumers with boric ointment and spiritus salicylowy, which are widely available in chemists/pharmacies and have accessible prices.
GSK Consumer Healthcare and Johnson & Johnson will rank first and second in dermatologicals respectively in value terms in 2020, with both companies expecting to see a rise in their retail current value shares. GSK Consumer Healthcare’s wide portfolio of brands benefits from a strong and wide distribution network, with the company’s Lamisil brand expected to retain its leadership in topical antifungals in 2020, and other strong brands including Zovirax in cold sore treatments and Fenistil in topical allergy remedies/antihistamines also expecting to increase their value shares in 2020.
The future development of this category is directly related to the health of the country’s economy. If the government continues its policy of opening the country to investment, and improving the local business environment, consumers will continue to purchase more diverse products and choose higher quality brands.
In general terms, the landscape of dermatologicals in Uzbekistan is expected to remain largely the same throughout the forecast period. The category will continue to be made up of a combination of international and local brands, with the latter gaining in strength through lower prices that are more attractive to consumers.
Both topical antifungals and vaginal antifungals expect to recover from the decline in retail volume sales seen towards the end of the review period with strong and rising growth rates throughout the forecast period. The temporary decline in volume sales expected in 2020 will be a result of increased home seclusion which, where topical antifungals are concerned, results in people spending less time wearing shoes or participating in sports.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Uzbekistan with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Uzbekistan, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page